Jeroen Hiltermann

Jeroen Hiltermann is a Researcher affiliated with the Faculty of Medical Sciences at the University of Groningen, part of the Translational Immunology Groningen (TRIGR) group. His work focuses on advanced lung cancer therapies, immune checkpoint inhibitors, and biomarker-driven treatment models. He has authored over 167 publications and actively participates in academic activities such as lectures, conferences, and tumor board discussions.

Research Interests:

• Non-small cell lung cancer (NSCLC) treatment optimization
• Immune checkpoint inhibitor mechanisms and side effects
• Biomarker-based prognostic modeling
• Lung cancer screening innovations (e.g., electronic nose technology)

Awards: TLCR Outstanding Author (2025) for contributions to cancer research. His work aligns with UN Sustainable Development Goals related to health and well-being.

Key Collaborations: Multicenter studies on lung cancer detection and immune-related adverse events. Active in clinical trials evaluating novel therapies like anti-PD-1/TIGIT bispecifics.